Results 251 to 260 of about 70,747 (277)

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Lancet, The, 2012
Jeffrey A Cohen, Alasdair J Coles, Douglas L Arnold   +2 more
exaly  

Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway

Science, 2013
Jiaxi Wu, Fenghe Du, Xiang Chen
exaly  

Fingolimod/interferon-beta-1b

Reactions Weekly
openaire   +2 more sources

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

Lancet, The, 2014
Eric Lawitz, Mark S Sulkowski, Zobair M Younossi   +2 more
exaly  

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

Lancet, The, 2005
Harry La Janssen, Yilmaz Cakaloglu, Guido Gerken   +2 more
exaly  

Interferon Beta-1B

2018
openaire   +1 more source

Multiple Sclerosis, interferon beta-1b and depression

Journal of Neurology, 2002
Anthony Feinstein, Paul O'Connor, Karen Feinstein   +2 more
openaire   +1 more source

Interferon-inducible effector mechanisms in cell-autonomous immunity

Nature Reviews Immunology, 2012
John D Macmicking
exaly  

Interferon-λ orchestrates innate and adaptive mucosal immune responses

Nature Reviews Immunology, 2019
Liang Ye, Daniel Schnepf, Peter Staeheli
exaly  

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

Lancet, The, 2014
Michael Manns, Maria Buti, Ewa Janczewska   +2 more
exaly